Preparation method and application of novel benzofuran component in eupatorium chinense

By extracting and preparing the benzofuran compound Eupbenzofuran A from the root of Wazelan, the problem of insufficient activity of existing α-glucosidase and PTP1B inhibitors was solved, and a significant inhibitory effect was achieved, which was used to treat diabetes and obesity. New drug options are available.

CN118994069AActive Publication Date: 2024-11-22CHINA THREE GORGES UNIV

Patent Information

Application Number
CN202410991934.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-22
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

The existing α-glucosidase and PTP1B inhibitors have problems with insufficient pharmacological activity and major side effects in clinical applications, and there is a lack of compounds with inhibitory activity extracted from the roots of Wazelan.

Method used

A new compound Eupbenzofuran A was prepared by extracting benzofuran compounds from the roots of Huazelan, using solvent extraction, macroporous adsorption resin removal, reverse phase silica gel column chromatography and HPLC to inhibit α-glucoside. Enzyme and PTP1B activity.

Benefits of technology

The compound Eupbenzofuran A significantly inhibits the activity of α-glucosidase and PTP1B, has potential drug application prospects for the treatment of diabetes and obesity, and provides new drug development directions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994069A_ABST
    Figure CN118994069A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a novel benzofuran component in eupatorium chinense. The compound is obtained by being separated from an extraction part of the eupatorium chinense. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, HW-40F gel column chromatography, high performance liquid chromatography and other methods to obtain a new benzofuran compound. The inhibitory activity of the separated compound on diabetes related targets alpha-glucosidase and protein tyrosine phosphatase 1B (PTP1B) is tested, the experimental result shows that the compound has good inhibitory activity on two enzymes, and the molecular docking experiment also shows that the compound has good inhibitory activity on the two enzymes. The compound has good binding energy with two target proteins alpha-glucosidase and protein tyrosine phosphatase 1B, so that the compound can be used for preparing drugs for preventing, delaying or treating alpha-glucosidase or PTP1B-mediated diseases, especially type II diabetes and obesity, or can be used as a lead compound of the drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biology and medicine technology, and relates to the separation, purification and application of benzofuran compounds from the root of Herba Cynoglossi, and specifically to a separation, purification and preparation method of a new benzofuran compound from the root of Herba Cynoglossi, and its inhibitory activity on α-glucosidase and protein tyrosine phosphatase 1B (PTP1B). Background Art

[0002] Huazelan is a perennial herbaceous plant of the genus Zeulan in the Asteraceae family. Its dried rhizomes are used as medicine in the folks to treat diphtheria, sore throat and other throat diseases. It is known as the "holy medicine for throat diseases". It is a commonly used Chinese herbal medicine in western Hubei, the Tujia ethnic group in western Hunan and Guangdong Province. Its chemical components mainly include terpenes, flavonoids, benzofurans, etc. Studies have shown that it has pharmacological activities such as anti-tumor, protein tyrosine phosphatase (PTP1B) inhibition, anti-inflammatory, antibacterial, antiviral and hypoglycemic (Li Degang, Ke Yinqian, Zou Kun, et al. Study on the anti-inflammatory activity of chemical components of petroleum ether parts of Huazelan rhizomes. Chinese Pharmacology and Clinical Medicine. 2022, 38(03): 106-110.).

[0003] α-glucosidase exists in the small intestinal mucosa and is one of the main target enzymes for controlling postprandial blood sugar. It converts carbohydrates in food into glucose and uses its reversible competition with sugar molecules for enzyme binding sites on the small intestinal brush border membrane epithelial cells to delay the formation of monosaccharides, thereby achieving a balance in blood sugar concentration. Currently, α-glucosidase inhibitors are one of the first-line drugs for the clinical treatment of type 2 diabetes.

[0004] The protein-tyrosine phosphatases (PTPs) family is a class of receptor-like cytoplasmic signal transduction enzymes that dephosphorylate the tyrosine residues of their substrates (Kim et al ., Int. J. Mol. Sci. 2018, 19: 2708), thereby regulating the metabolic processes of various cells and maintaining body homeostasis. Protein tyrosine phosphatase 1B (PTP1B) is a typical non-transmembrane tyrosine phosphatase and a negative transducer of insulin signaling. Insulin resistance, especially insulin resistance in adipose tissue and muscle, is closely related to the occurrence of type 2 diabetes mellitus (T2DM) (Eur. J. Pharmacol. 2005, 519: 182-190; Kim et al., J. Clin. Invest. 2000, 105: 1791-1797). In addition, in the study of breast cancer, ovarian cancer and prostate cancer, PTP1B overexpression can be detected, and PTP1B overexpression can be detected at all stages of tumor development (Mol. Cell. Biol. 1998, 18, 2965-2975; J. Natl. Cancer Inst. 1996, 86, 372-378), indicating that PTP1B is closely related to many important tumor formation signaling pathways. Therefore, PTP1B inhibitors can be used to treat or prevent cancer or to slow down its progression when cancer develops. Simultaneous inhibition of α-glucosidase and PTP1B can reduce postprandial blood sugar on the one hand, and enhance insulin sensitivity and reduce the load of pancreatic β cells on the other hand, jointly maintaining the stability of blood sugar levels in the body, and can reduce the body weight of obese diabetic patients by increasing leptin levels in the body.

[0005] Natural products (especially those derived from plants) have always been an important source for discovering innovative drugs with novel structures and new mechanisms of action (J. Nat. Prod. 2020, 83: 770-803). Plant active ingredients have the characteristics of diverse skeletons, novel structures, multiple targets, and low toxicity and side effects; they are often selected and evolved by natural laws, can effectively bind to biological macromolecules, and show good activity. Therefore, it is of great research value to screen and discover new and efficient α-glucosidase and PTP1B inhibitors from active ingredients derived from plants. Summary of the invention

[0006] The first purpose of the present invention is to provide a benzofuran compound from the root of Herba Cyperi and a preparation method thereof. The second purpose is to provide a use of the compound in the preparation of a drug for preventing or treating diseases mediated by α-glucosidase or protein tyrosine phosphatase PTP1B. The compound having the activity of inhibiting α-glucosidase or PTP1B has the following structural formula:

[0007] Eupbenzofuran A, compound 1.

[0008] The technical solution of the present invention is to use a benzofuran compound extracted from the root of Huazelan in the preparation of drugs for preventing, delaying or treating diseases mediated by α-glucosidase or protein tyrosine phosphatase PTP1B.

[0009] The preparation method of the Huazelan acetylene compound comprises the following steps: A1. Solvent extraction: The root of Huazelan is crushed and extracted with ethanol, petroleum ether, ethyl acetate and n-butanol in sequence, and the n-butanol extract is concentrated to obtain extract a; B1. Extract a macroporous adsorption resin impurity removal: extract a is added with deionized water and ultrasonically dissolved, macroporous adsorption resin (D101 type) is soaked in deionized water and loaded onto the column, rinsed, wet loaded, left to stand overnight for adsorption, eluted with ethanol / deionized water system, and the eluate is concentrated under reduced pressure to obtain extract b; C1. Dissolve the extract b in methanol, and use reversed-phase silica gel column chromatography to crudely separate the extract. Use wet column packing, dry sample loading, and use a methanol / deionized water system for gradient elution to collect the eluate. D1, taking the eluate and performing preliminary separation by reverse silica gel column chromatography to obtain a separated product; E1. The separated product was separated by HW-40F gel column chromatography, and the obtained fragments were prepared by semi-preparative HPLC to obtain compound 1.

[0010] In step C1, 10% methanol / 90% water, 15% methanol / 85% water, 20% methanol / 80% water, 30% methanol / 70% water, 40% methanol / 60% water, 60% methanol / 40% water, 80% methanol / 20% water and 100% methanol are used for gradient elution, and the eluate of the 60% methanol / 40% water portion, the eluate of the 80% methanol / 20% water portion, or the eluate of the 100% methanol portion is collected.

[0011] The eluent in step D1 is sequentially separated by reverse silica gel column chromatography with 10% methanol / water, 20% methanol / water, 30% methanol / water, 40% methanol / water, 50% methanol / water, 60% methanol / water, 70% methanol / water, 80% methanol / water, 90% methanol / water and 100% methanol to collect the separated products of 90% methanol / water and / or 100% methanol.

[0012] In step E1, the separated product is separated by HW-40F gel column chromatography using methanol-water at a volume fraction of 60-75: 25-40; In the semi-preparative HPLC, the mobile phase is acetonitrile-water 60:40, and the flow rate is 1-2 mL / min.

[0013] A medicine for treating diabetes and obesity, comprising the prepared compound 1.

[0014] A compound for inhibiting the activity of alpha-glucosidase or PTP1B, comprising the prepared compound 1.

[0015] A drug for preventing, delaying or treating diabetes and obesity is prepared by inhibiting the activity of alpha-glucosidase or PTP1B, and the drug comprises the prepared compound 1.

[0016] The compound 1 is prepared by α - The amino acids in the active site of the glucosidase protein combine to form a site containing hydrophobic interactions and hydrogen bond interactions; The compound 1 combines with the amino acids in the active site of the PTP1B protein to form a site containing hydrophobic interactions and hydrogen bond interactions.

[0017] The compound or drug of the present invention further includes a pharmaceutically acceptable excipient.

[0018] Compared with the prior art, the present invention has at least one of the following beneficial effects: 1. Compound 1 of the present application has significant α-glucosidase or PTP1B inhibitory activity, and there is no public report on the α-glucosidase or PTP1B inhibitory activity of the compound and its application in related diseases.

[0019] 2. For the first time, a compound with the ability to inhibit α-glucosidase or PTP1B activity was isolated from the n-butanol extract of the root of Huazelan. This has broad application prospects for the development of drugs that can prevent or treat α-glucosidase or PTP1B-mediated diseases, such as diabetes and obesity. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The chemical structure diagram of compound 1.

[0021] Figure 2 For compound 1 1 H-NMR.

[0022] Figure 3 For compound 1 13 C-NMR.

[0023] Figure 4 This is the DEPT135 spectrum of compound 1.

[0024] Figure 5 is the HSQC spectrum of compound 1.

[0025] Figure 6 For compound 1 1 H- 1 H COSY spectrum.

[0026] Figure 7 is the HMBC spectrum of compound 1.

[0027] Figure 8 is the NOESY spectrum of compound 1.

[0028] Fig. 9 This is the experimental ECD spectrum of compound 1.

[0029] Fig.10 This is the ECD spectrum calculated by TD-DFT theory for compound 1.

[0030] Fig.11 This is an analysis diagram of the interaction between compound 1 and α-glucosidase protein (wherein, A: 3D binding mode of compound 1 and α-glucosidase protein; B: amino acid residue binding mode of compound 1 and α-glucosidase protein; C: 2D binding mode of compound 1 and α-glucosidase protein).

[0031] Fig.12 This is an analysis diagram of the interaction between compound 9 and PTP1B protein (wherein, A: 3D binding mode of compound 9 and PTP1B protein; B: amino acid residue binding mode of compound 9 and PTP1B protein; C: 2D binding mode of compound 9 and PTP1B). DETAILED DESCRIPTION

[0032] The following implementation cases are used to further explain the present invention. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application.

[0033] Example 1: Separation and purification of a benzofuran compound extracted from the root of Herba Cyperi The preparation method comprises the following steps: Step A, solvent extraction: the root of Huazelan was dried and crushed, and refluxed and extracted with 95% ethanol for 3 times at room temperature. After concentration by rotary evaporator, the extract was dispersed in water, and extracted with petroleum ether, ethyl acetate, and n-butanol in sequence, and each was repeated three times. The n-butanol extract was concentrated to obtain extract a; Step B, impurity removal of extract a with macroporous adsorption resin: take extract a, add 300 g deionized water and ultrasonically dissolve it, soak 1000 g macroporous adsorption resin (type D101) in deionized water for 6 hours and then load it onto the column, rinse with deionized water for at least three column volumes, lower the solvent to about 2 cm above the filler surface, wet load, let stand overnight for adsorption, elute with 50% ethanol / 50% deionized water, rinse until the eluent is colorless, and concentrate the eluent under reduced pressure to obtain extract b.

[0034] Step C, column chromatography crude fractionation: Take the above extract b, dissolve it with a small amount of methanol, add it to 90g reverse phase silica gel (200-300 mesh), and mix the sample; weigh 1200g reverse phase silica gel, soak it with 10% methanol / 90% deionized water, use wet column packing, the column volume is 1 L, rinse with 10% methanol / 90% deionized water for at least three column volumes until the solvent level in the column is about 2 cm higher than the filler surface, use dry method to load the sample, after loading the sample, plug in an appropriate amount of absorbent cotton as a protective layer, combine the results of high performance liquid phase analysis, use methanol-water system to elute, and perform preliminary separation of extract b. Gradient elution was performed with 10% methanol / 90% water, 15% methanol / 85% water, 20% methanol / 80% water, 30% methanol / 70% water, 40% methanol / 60% water, 60% methanol / 40% water, 80% methanol / 20% water and 100% methanol, respectively, with each gradient washing for 2 column volumes to obtain 8 fractions (Fr.AH).

[0035] Thin layer chromatography, high performance liquid chromatography and HPLC-DAD scanning analysis showed that the 60% methanol / 40% water portion Fr.F was the component where the target compound was located.

[0036] Step D, take the 60% methanol / 40% water fraction Fr.F for high performance liquid analysis (analysis conditions: 10% methanol / water to 100% methanol, 30 minutes, flow rate 1 mL / min, wavelength 203 nm), and after preliminary separation by reverse silica gel column chromatography (10% methanol / water to 100% methanol), 10 components Fr.F (1-10) were obtained.

[0037] The reverse silica gel column chromatography refers to: 10% methanol / water, 20% methanol / water, 30% methanol / water, 40% methanol / water, 50% methanol / water, 60% methanol / water, 70% methanol / water, 80% methanol / water, 90% methanol / water, 100% methanol. HPLC-DAD scanning analysis shows that Fr.F-9 is the component where the target compound is located.

[0038] Step E: Fr. F-9 was initially separated by HW-40F gel column chromatography (methanol-water 75:25, volume ratio) to obtain four fragments (Fr. F9-1 ​​to F9-4). Compound 1 (5.9 mg) was obtained from Fr. F-9-3 by semi-preparative HPLC (acetonitrile-water 60:40, 2 mL / min, YMC C18 column).

[0039] The NMR spectrum data and mass spectrum data of compound 1 are as follows: Compound 1: Colorless oily liquid. Optical rotation data [α] 25 D +8.6° (c 0.10, methanol), UV (methanol) λ max =239, 350 nm; by high resolution mass spectrometry HR-ESI-MS m / z : 313.1059 [M+Na] + (C 16 H 18 NaO5, calcd.313.1052), its molecular formula is determined to be C 16 H 18 O5, unsaturation is 8. Analysis of compound 1 1 H-NMR spectrum (Table 1) shows two olefin proton signals δ H 8.31 (H-4) and 7.07 (H-7), the compound has 3 methyl groups ( δ H 2.72 (H-16), 1.50 (H-17) and 1.45 (H-14). 13 The C-NMR spectrum and DEPT135 spectrum show 16 carbon signals, including 3 methyl carbon signals. δ C 27.9 (C-16), 27.9 (C-17) and 27.2 (C-14); 2 methylene carbon signals δ C 37.69 (C-12) and δ C 36.77 (C-11); 2 oxygen-linked carbon signals δ C 68.74 (C-10) and 65.69 (C-13); 1 carbonyl carbon signal δ C 205.05 (C-15); 8 olefin carbon signals δ C 160.04 (C-6), 158.92 (C-8), 156.9 (C-2), 124.9 (C-4), 120.7 (C-5), 119.7 (C-9), 117.22 (C-3), 99.52 (C-7).

[0040] Table 1. Comparison of compound 1 with reference compounds 1 H-NMR and 13 C-NMR data comparison (solvent DMSO- d 6)

[0041] In the HMBC spectrum, it can be observed that δ H 1.50 (H-17), δH 1.73 (H-11), respectively and δ C 65.69 (C-10) is correlated, confirming the presence of hydroxyl and methyl groups at C-10. In the HMBC spectrum, there are correlations between H-14 and C-13, C-12, and C-2, and between H-16 and C-15 and C-5; 1 H- 1 In the H COSY spectrum, there is a correlation between H-11 and H-12. Thus, the planar structure of compound 1 was obtained ( Figure 1 ).

[0042] In the NOESY spectrum ( Figure 8 ) β 、H-14 / H-11 β The correlation between H-14 and C-17 indicates that H-14 and C-17 are on the same side of the C ring. Finally, the relative configuration of compound 1 is determined. Its absolute configuration is calculated by TD-DFT theory ECD spectrum ( Fig.12 ) and experimental ECD spectrum ( Fig.11 ) (positive cotton effect at 242 nm and positive cotton effect at 360 nm) and determined to be 10 S、 13 R, After searching, it was found to be a new compound and named Eupbenzofuran A.

[0043] Example 2: Test of the inhibitory activity of compound 1 on α-glucosidase and PTP1B Experimental methods α-Glucosidase activity assay The α-glucosidase assay was modified according to the method of Tao et al. (Biomedical chromatography: BMC. 2013, 27(2): 148-155). The p-nitrophenyl-β-pyranogalactoside method was used. pNPG was used as a substrate and was decomposed into pNP and glucose under the catalysis of α-glucosidase. pNP was yellow and had strong ultraviolet absorption at 405 nm. Acarbose was used as a positive control to detect the amount of product after adding the sample to determine the inhibition rate of the sample. 80 μL of sample (n-butanol extract of Huazelan or compound 1) solution (PBS buffer at pH 7.2) and 20 μL of α-glucosidase (2 U / mL, pH 7.2 PBS buffer), mixed thoroughly. After incubation at 37 °C for 15 min, 20 μL of 5 mmol / L pNPG was added to start the reaction. After incubation for 15 min, 80 μL of 1 mol / L Na2CO3 was added to terminate the reaction. 80 μL of 1% PBS was added to the blank control group instead of the sample solution. The absorbance (A) at 405 nm was used to quantify the release of pNPG. The enzyme activity group (enzyme 20 μL + reaction buffer 80 μL + substrate 20 μL), enzyme blank group (reaction buffer 100 μL + substrate 20 μL), sample group (sample 80 μL + enzyme 20 μL + substrate 20 μL), sample blank group (sample 80 μL + reaction buffer 20 μL + substrate 20 μL) were set up, and acarbose solution was used as the positive control. The inhibition rate was calculated by the following formula: inhibition rate = 1-(A sample-A sample blank) / (A enzyme activity-A enzyme blank).

[0044] PTP1B enzyme activity assay The determination method of PTP1B was referred to the literature ( Funct. Foods , 2018, 41:232-239; Acta Pharmaceutica Sinica, 2019, 54(3): 510-513.) 10 μL of sample (n-butanol extract of Huazelan or compound 1) was added to 170 μL of reaction buffer solution (composed of 50 mM citric acid (pH 7.4), 50 mM NaCl, 2 mM dithiothreitol (DTT), 1.1 mM EDTA), 20 μL of recombinant PTP1B solution (1 mg / mL, 1 μL) was added and mixed in each well, the reaction mixture was preheated for 15 min using a block heater at 37°C, 10 μL of reaction substrate p-nitrophenyl phosphate pNPP (33 mM) was added, the reaction was reacted at 37°C for 15 min, and NaOH solution (10 μL, 0.1 M) was added to stop the reaction. The absorbance was recorded at 405 nm. According to the above steps, the enzyme activity group (enzyme 20 μL + reaction buffer solution 170 μL + substrate 10 μL), enzyme blank group (reaction buffer 190 μL + reaction substrate 10 μL), sample group (sample 170 μL + enzyme 20 μL + reaction substrate 10 μL), and sample blank group (sample 170 μL + reaction buffer solution 20 μL + reaction substrate 10 μL) were set up, and sodium orthovanadate aqueous solution and oleanolic acid solution were used as positive controls.

[0045] The inhibition rate was calculated according to the following formula: Inhibition rate = 1-(A sample-A sample blank) / (A enzyme activity-A enzyme blank) Experimental results: The α-glucosidase and PTP1B enzyme inhibition activities of the n-butanol extract of Huazelan and compound 1 were tested. The results are shown in Tables 2~3: Table 2. Results of the inhibition of α-glucosidase activity by compound 1

[0046] The test results show that the above-mentioned benzofuran compounds from the roots of Huazelan have good α-glucosidase inhibitory activity.

[0047] Table 3. Results of compound 1 inhibiting PTP1B enzyme activity

[0048] The test results show that the above-mentioned benzofuran compounds in the roots of Huazelan have certain PTP1B enzyme inhibitory activity.

[0049] Example 3: Docking of Compound 1 with two protein target molecules The compound 1 for this docking was constructed using ChemDraw, and then imported into Chem3D software for optimization and energy minimization using the MM2 module, and saved as an sdf format file as the ligand molecule for molecular docking. It was then imported into Pymol and Autodock software for optimization and exported as a PDBQT file. The protein structures of α-glucosidase (PDB ID: 5ZCE) and PTP1B (PDB ID: 5QG3) are from the RCSB database ( https: / / www.rcsb.org / ), the protein structure was treated with water molecules, ligands, hydrogenation, etc. on the Pymol and Autodock platforms, and the protein was energy minimized and the geometry optimized and exported as a PDBQT file. The molecular docking processing and optimization were completed by the Grid module in the Autodock software. The PDBQT file in Example 2 was imported into the software, and the box was fully wrapped around the protein, and then molecular docking was performed. In addition, the complex of protein and small molecule was visualized and analyzed using Pymol.

[0050] Docking results Molecular docking results Table 4. Docking results of compound 1 and target protein Target protein Compound Binding energy (kcal / mol) α-Glucosidase 1 -7.9 PTP1B 1 -20.8 Analysis of compound-protein interactions In this experiment, compound 1 was combined with α -glucosidase and PTP1B target protein were molecularly docked. The molecular docking results showed that the compound had a good binding effect with the target protein and the matching degree was high ( Fig.11 and Fig.12), the binding energy is less than -6 kcal / mol. The complex formed by the docking compound and the protein was visualized using Pymol2.1 software to obtain the binding mode of the compound and the protein. According to the binding mode, the amino acid residues that bind to the compound and the protein pocket can be clearly seen. Compound 1 and α The amino acids PHE-163 and ALA-200 in the active site of the -glucosidase protein form multiple hydrophobic interactions and form multiple hydrogen bond interactions with amino acids GLN-256, ASP-327, GLN-328, and ARG-411.

[0051] Compound 1 forms multiple hydrophobic interactions with GLU-75, GLU-76, LEU-234, LYS-248, VAL-249, and GLU-252 amino acids in the active site of the PTP1B protein, and forms multiple hydrogen bond interactions with GLU-76, ALA-77, ARG-238, and VAL-249 amino acids; it has strong binding ability and plays an important role in anchoring small molecules in the protein pocket.

[0052] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Benzofuran compounds from the root of Herba Cynanchifoliae, characterized in that: The structural formula is as follows: Compound 1.

2. The method for separating and extracting benzofuran compounds from the root of Herba Cyperi chinensis according to claim 1, characterized in that: The steps include: A1. Solvent extraction: The root of Huazelan is crushed and extracted with ethanol, petroleum ether, ethyl acetate and n-butanol in sequence, and the n-butanol extract is concentrated to obtain extract a; B1. Extract a macroporous adsorption resin impurity removal: extract a is added with deionized water for ultrasonic dissolution, macroporous adsorption resin is soaked in deionized water and loaded onto the column, rinsed, wet loaded, left to stand overnight for adsorption, eluted with ethanol / deionized water system, and the eluate is concentrated under reduced pressure to obtain extract b; C1. Dissolve the extract b in methanol, and use reversed-phase silica gel column chromatography to crudely separate the extract. Use wet column packing, dry sample loading, and use a methanol / deionized water system for gradient elution to collect the eluate. D1, taking the eluate and performing preliminary separation by reverse silica gel column chromatography to obtain a separated product; E1. The separated product was separated by HW-40F gel column chromatography, and the obtained fragments were prepared by semi-preparative HPLC to obtain compound 1.

3. The method for separating and extracting benzofuran compounds from the root of Herba Cynanchifoliae according to claim 2, characterized in that: In step C1, 10% methanol / 90% water, 15% methanol / 85% water, 20% methanol / 80% water, 30% methanol / 70% water, 40% methanol / 60% water, 60% methanol / 40% water, 80% methanol / 20% water and 100% methanol are used for gradient elution, and the eluate of the 60% methanol / 40% water portion, the eluate of the 80% methanol / 20% water portion, or the eluate of the 100% methanol portion is collected.

4. The method for separating and extracting benzofuran compounds from the root of Herba Cyperi chinensis according to claim 2, characterized in that: The eluent in step D1 is sequentially separated by reverse silica gel column chromatography with 10% methanol / water, 20% methanol / water, 30% methanol / water, 40% methanol / water, 50% methanol / water, 60% methanol / water, 70% methanol / water, 80% methanol / water, 90% methanol / water and 100% methanol to collect the separated products of 90% methanol / water and / or 100% methanol.

5. The method for separating and extracting benzofuran compounds from the root of Herba Cyperi chinensis according to claim 2, characterized in that: In step E1, the separated product is separated by HW-40F gel column chromatography using methanol-water at a volume fraction of 60-75: 25-40; In the semi-preparative HPLC, the mobile phase is acetonitrile-water 60:40, and the flow rate is 1-2 mL / min.

6. A drug for treating diabetes and obesity, characterized in that: The drug comprises the compound 1 according to claim 1.

7. A compound for inhibiting the activity of α-glucosidase or PTP1B, characterized in that: The compound includes the compound 1 according to claim 1.

8. A method for preparing a drug for treating diabetes and obesity by inhibiting the activity of α-glucosidase or PTP1B, characterized in that: The drug comprises the compound according to claim 1.

9. The compound or drug according to claim 7 or 8, characterized in that The compound 1 of claim 1 is prepared by α - The amino acids in the active site of the glucosidase protein combine to form a site containing hydrophobic interactions and hydrogen bond interactions; The compound 1 described in claim 1 combines with the amino acids in the active site of the PTP1B protein to form a site containing hydrophobic interactions and hydrogen bond interactions.

10. The compound or drug according to claim 6 or 9, characterized in that The compound or medicament also includes a pharmaceutically acceptable excipient.

Citation Information

Patent Citations

  • Preparation method and application of benzofuran compound in chinese eupatorium

    CN109232491A

  • Application of benzofuran dimer compound in preparation of medicine for treating diseases mediated by protein tyrosine phosphatase 1B

    CN117343035A

Cited By

  • Preparation method and application of Eupatorium chinense n-butyl alcohol effective part extract

    CN120114496A

  • Benzofuran compound, preparation method thereof and gout medicine

    CN122255145A